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Purpose: The present study was designed to determine the association of polymorphisms of the DNA repair genes X-ray
cross-complementing group 1 (XRCC1) (c.1316G>A [rs25487]) and xeroderma pigmentosum complementation group D
(XPD) (c.2298A>C [rs13181]) with primary open-angle glaucoma (POAG) and primary closed-angle glaucoma (PCAG).
Methods: In this prospective case-control study, polymerase chain reaction-restriction fragment length polymorphism
analysis was used to study the association of XRCC1 and XPD with 160 POAG patients, 163 PCAG patients, and 193
unaffected controls.
Results: XRCC1 rs25487 was found to be significantly associated specifically with male POAG patients (χ2=13.2
[p=0.001]), only for the dominant model (odds ratio [OR]=2.65 [95% confidence interval [CI]=1.44–4.85], p<0.005). In
addition XPD rs13181 was also found to be associated with male POAG patients (χ2=12.1 [p<0.005]), for both dominant
(OR=2.44 [95% CI=1.33–4.47], p<0.005) as well as recessive model (OR=3.62 [95% CI=1.45–9.01], p<0.01). Combined
genotypes of both the genes revealed that the heterozygote AC/GA was significantly associated with the male POAG
patients (z=3.00 [p<0.001]). The AA/GG genotype was present at a higher frequency in the male controls and the AA/
GA in the female controls and could thus have a protective role in males and females, respectively.
Conclusions: We postulate that defects in the DNA repair genes XRCC1 and XPD may possibly be associated with the
progression of POAG in male patients of Pakistani origin.
Glaucoma is a leading cause of irreversible blindness,
characterized by degeneration of the retinal ganglion cells and
optic nerve damage. Among the two common clinical types
primary open angle glaucoma (POAG) is the most prevalent
form, which is characterized by an obstruction of the aqueous
humor pathway as a result of trabecular meshwork
degeneration or decay. The other form primary close angle
glaucoma (PCAG) is characterized by closure of angle
between the iris and trabecular meshwork, mainly because of
anatomic abnormalities. Although the etiology of glaucoma
is not fully understood, there is strong evidence to suggest that
it is caused by a combination of environmental and genetic
factors [1].
Several studies support the involvement of oxidative
damage to DNA as a common factor of glaucomatous
neurodegeneration, which occurs in different subcellular
compartments of the retinal ganglion cells [2-4]. Many DNA
repair genes and their polymorphisms including the
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Xeroderma pigmentosum complementation group D (XPD,
also known as Excision Repair Cross-complementation group
2 [ERCC2]), and the X-ray cross-complementing group 1
(XRCC1) have been reported to be associated with several
different diseases including glaucoma, which have been
shown to be dependent upon the genetics and ethnicity of the
individuals or environmental factors [5].
XRCC1 on chromosome 19q13.2 encodes a multi-domain
protein that interacts with nicked DNA and is involved in
single-strand breaks and base excision repair (BER) pathway
in response to DNA damage caused by ionizing radiation,
alkylating agents and oxidation. Different XRCC1 mutations
have been shown to disrupt the function of the protein by
affecting its binding to the substrate or by introducing changes
in the catalytic domain [6]. A single nucleotide polymorphism
(SNP; c.1316G>A; p.Arg399Gln, rs25487), located near the
breast cancer C-terminal domain (BRCT), is involved in cell
cycle checkpoint functions that are initiated in response to
DNA damage. This BRCT domain interacts with the poly-
ADP-ribose polymerase binding domain of Poly (ADP-
ribose) polymerase-1, which is an enzyme involved in the
BER pathway [7]. Therefore any change in the structure of
BRCT has the potential to lead to defects in the detection of
the DNA damage and hence the activation of the BER
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pathway. Although no direct functional evidence is available
that the variant c.1316A allele interrupts the interaction
between BRCT and Poly (ADP-ribose) polymerase-1, but
indirect functional analysis using biomarkers, such as
chromosomal aberrations, have shown that cancer patients
with the c.1316A allele have a significantly higher number of
chromosomal aberrations (such as deletions) and greater
number of DNA adducts as compared to individuals with wild
type c.1316G allele, indicative of defects in the BER pathway
[8,9].
XPD encodes an ATP-dependent DNA helicase present
1.8 Mb downstream of XRCC1 on chromosome 19q13.3, it is
an important component of the Transcription Factor IIH that
is involved in nucleotide excision repair (NER) of UV induced
damage and removal of bulky adducts [5]. Genetic variations
in XPD are associated with defects in the NER mechanism
[10] resulting in autosomal recessive DNA repair disorders.
Two SNPs in XPD, p.Asp312Asn (rs1799793) and
p.Lys751Gln (rs13181), have been shown to be involved in
susceptibility to various types of cancer in addition to various
inherited and age related diseases [7,11]. The rs13181 affects
an ATP-binding site of XPD and destroys its helicase activity,
which is important for NER, but does not affect its
transcriptional activity [12]. The lysine at codon 751 is
assumed to be involved in interactions with the substrate of
XPD, thus any substitution at this residue may produce
changes in its function which can impair the DNA repair
capacity [13].
Up to the present date there is no data available that shows
a significant association of the polymorphisms of DNA repair
genes with glaucoma in any specific ethnic group [14]. The
aim of the present study was therefore to investigate the
relationship between polymorphisms of the DNA repair genes
and two different forms of glaucoma in the Punjabi Pakistani
population. Our study is the first from Pakistan to report
ethnic-based associations of the XRCC1 and XPD
polymorphisms with male POAG patients.
METHODS
Patient selection criteria: This study conforms to the tenants
of the Helsinki declaration and has been approved by the
Departmental Review and Ethics Committee. All subjects
were briefed about the study in their local language and
informed written consent was obtained from them before
obtaining their blood samples. The study group consisted of
Punjabi’s which are the major ethnic group of Pakistan. The
affected arm was composed of 323 Punjabi patients consisting
of 160 POAG (80 males, 80 females) and 163 PCAG cases
(81 males, 82 females), in addition DNA samples of 193
unaffected (101 males, 92 females) age and sex matched
Punjabi control individuals were also studied. The inclusion
criteria for patients/controls, clinical examination, as well as
collection and processing of the whole blood have been
described previously [15]. In addition to the isolated glaucoma
patients, 9 Punjabi families (29 patients, 68 unaffected) of
congenital POAG were also screened to study the association
of the two SNPs in these families. Briefly, blood samples from
controls, patients and family members were collected in
EDTA tubes and genomic DNA was extracted by a
conventional phenol chloroform method [16].
Polymerase chain reaction (PCR) amplification of genomic
DNA: The XRCC1 codon 399 and XPD codon 751
polymorphisms were detected by PCR-RFLP. A 242 base pair
(bp) fragment containing the polymorphism rs25487 (c.
1316G>A; p.Arg399Gln) in exon 10 of the XRCC1 gene was
amplified using the primers: 5′-CCC CAA GTA CAG CCA
GGT C-3′ (forward) and 5′-TGT CCC GCT CCT CTC AGT
AG-3′ (reverse). A 436-bp fragment containing the
polymorphism rs13181 (c.2298A>C; p.Lys751Gln) in exon
23 of the XPD gene was amplified using the primers 5′-GCC
CGC TCT GGA TTA TAC G-3′(forward) and 5′-CTA TCA
TCT CCT GGC CCC C-3′ (reverse). The 25 µl-PCR reaction
for each polymorphism contained 1× PCR buffer, 1.5 mM
MgCl2 (Fermentas, Burlington, Ontario), 10 pmol of each
primer, 0.2 mM deoxy nucleotide triphosphates (dNTPs;
Fermentas, Burlington, Ontario), 1 U Taq polymerase
(Biotools, Madrid, Spain) and 50 ng genomic DNA as
template. The PCR thermal cycling profile consisted of an
initial denaturation at 95 °C for 5 min followed by 35 cycles
of 1 min DNA denaturation at 95 °C, primer annealing for 45
s at 60 °C, 1 min extension at 72 °C, followed by one cycle of
a final extension step for 7 min at 72 °C. The amplifications
were performed with an Applied BioSystem Gene Amp® PCR
system 2700 (Foster City, CA).
Restriction fragment length polymorphism (RFLP) analysis
of XRCC1: The PCR products were digested with MspI
restriction enzyme (Fermentas, Burlington, Ontario) at 37 °C
overnight, followed by electrophoretic separation on 2.5%
agarose gels, along with a 100 bp DNA ladder (Invitrogen Inc.,
Carlsbad, CA). The “A” allele of the polymorphism rs25487
degenerates a MspI restriction site, resulting in two fragments
of 148 and 94 bp for the GG genotype, three fragments of 242,
148, and 94 bp of the AG genotype, and a single fragment of
242 bp for the AA genotype (Figure 1).
RFLP analysis of XPD: The PCR amplified products were
digested with PstI restriction enzyme (Fermentas) overnight
at 37 °C and the fragments were resolved on 4% agarose gel.
The “C” allele of the polymorphism rs13181 creates a PstI
restriction site. The AA genotype results in two fragments of
290 and 146 bp, four fragments of 290, 227, 146, and 63 bp
for the AC genotype, and three fragments of 227, 146, and 63
bp for the CC genotype (Figure 1).
Sequence analysis of XRCC1 and XPD genotypes: To validate
the RFLP results 5 random samples of each genotype of
rs25487 (n=15) and rs13181 (n=15) were sequenced using the
primers described above for the PCR amplification of these
SNP’s (Figure 2A-F).
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Statistical analysis: The demographic features (age, Intra
Ocular Pressure [IOP], and Cup to Disk Ratio [CDR]),
genotype, and allele distribution of both patient and controls
were analyzed by using SPSS (ver. 16; SPSS, Chicago, Il) and
the level of significance of the clinical parameters were tested
using Minitab (ver. 15; Minitab, Chicago, Il). The genotype
and allele frequency differences between POAG, PCAG,
controls, and affected/non-affected family members were
compared by chi square (χ2) and/or z tests, a p-value <0.05
was considered to be statistically significant.
RESULTS
In the present study the mean age of controls was 39.7±11.9
and 41.3±13.7 for POAG, and 43.6±15.8 years in case of
PCAG patients, there being no statistically significant dif-
ference in the ages of the three groups. In most of the patients
the disease was diagnosed at an advance stage, therefore an
early onset of the disease cannot be precluded. In all the
patients there was no evidence of systemic diseases like
diabetes, hypertension, etc. in addition the development of
secondary glaucoma due to some other eye anomaly was also
ruled out. The mean IOP in the controls was
13.70±1.86 mmHg, which was significantly higher in the
POAG and PCAG patients (26.00±9.27 mmHg and
26.50±10.80 mmHg, respectively, p<0.001). Similarly, the
CDR in the control group was 0.30±0.11, which was
significantly larger in the POAG and PCAG patients (0.83±.
30 and 0.65±.23, respectively, p<0.001).
XRCC1 genotyping: For the POAG patients (Male
+Female) there was no significant difference in the overall
genotype (GG, GA, and AA) distribution as compared to Male
+Female control group (χ2=5.69 [p>0.05]; Table 1), although
the frequency of the GA genotype was significantly higher in
the patients (z=2.29 [p<0.05]). However, when the data were
analyzed along the lines of gender a highly significant
difference was observed between the genotype distribution of
the male POAG and control samples (χ2=13.2 [p=0.001];
Table 1), while no significant difference was observed in the
case of the females (χ2=2.93 [p>0.05]; Table 1). The
difference in the genotype frequency of the male POAG
patients was significant only under a dominant model (odds
ratio [OR]=2.65 [95% confidence interval [CI]=1.44–4.85],
p<0.005). As opposed to this analysis of the PCAG samples
revealed no significant difference in the overall genotype
distribution of Male+Female as compared to the controls
(χ2=0.25 [p>0.05]), as well as when the samples were
distributed along the lines of gender (Table 1).
The frequency of the risk allele “A” was 39% in the male
POAG patients, which was significantly higher from the 29%
in the male controls (χ2=4.56 [p<0.05], OR=1.61 [95%
CI=1.04–2.5], p<0.05; Table 1).
XPD genotyping: The overall genotype (AA, AC, and
CC) distribution in the POAG (Male+Female) and controls
was significantly different from each other (χ2=8.75 [p=0.01];
Table 2), which was statistically significant under the
dominant model only (OR=1.89 [95% CI=1.23–2.92],
p=0.005). As opposed to this no significant difference
between the genotype frequencies of PCAG and control
subjects was found (χ2=5.68 [p>0.05]).
When the POAG data were split along the lines of gender,
only the male genotype distribution was found to be
significantly different from the controls (χ2=12.1 [p<0.005]),
which was significant under the dominant model (OR=2.44
[95% CI=1.33–4.47], p<0.005) as well as the recessive model
(OR=3.62 [95% CI=1.45–9.01], p<0.01).
Compared to the male control individuals (26%) the
frequency of the risk allele “C” was significantly higher in the
POAG patients (44%) (χ2=12.96 [p<0.001], OR=2.24 [95%
CI=1.44–3.49], p<0.001).
Combined Genotypes of XRCC1 and XPD genes: The
combined genotypes of XPD and XRCC1 of the controls (Male
Figure 1. Agarose gel electrophoresis of the polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) analysis
of XPD and XRCC1. (Lanes 1–5) PstI digested fragments of exon 23 c.2298A>C XPD SNP. (Lane 1) AA genotype consisting of two fragments;
290 and 146 bp. (Lanes 2, 3, and 5) AC genotype consisting of four fragments; 290, 227, 146 and 63 bp. (Lane 4) CC genotype consisting of
three fragments; 227, 146, and 63 bp. (Lanes 6–9) MspI digested fragments of exon 10 c.1316G>A XRCC1 SNP. (Lane 7) GG genotype
consisting of two fragments; 148 and 94 bp. (Lanes 6 and 8) AG genotype consisting of three fragments; 242, 148, and 94 bp. (Lane 9) AA
genotype consisting of an undigested fragment of 242 bp.
Molecular Vision 2011; 17:1153-1163 <http://www.molvis.org/molvis/v17/a130> © 2011 Molecular Vision
1155
+Female) was significantly different in case of POAG
(χ2=20.44 [p=0.01]) and also in the case of male POAG
patients (χ2=27.04 [p<0.001]), but not for female POAG
patients (χ2=13.01 [p>0.05]) or for any distribution in the case
of PCAG. In addition the combined genotype, AC/GA of the
POAG patients (Male+Female) when compared to the
controls was found to be present at a significantly higher
frequency (z=3.42 [p<0.001], which was solely because of the
significantly higher frequency of AC/GA in the male patients
(z=3.00 [p<0.001]) and not because of the female patients
(z=1.82 [p>0.05]; Table 3), though the female patients AC/
GA frequency was greater than the female controls (24%
versus 13%) but not at a statistically significant level. The
combined genotypes AA/GG, was present at a higher
frequency in the controls (Male+Female) as compared to
POAG patients (Male+Female; z=2.14, [p<0.05]), which was
solely because of the higher frequency of this combined
genotype in the male controls (z=3.12 [p<0.001]). While the
AA/GA combined genotype was present at a higher frequency
in the female controls as compared to female POAG and
PCAG samples (z=2.17 [p<0.05] and z=2.24 [p<0.05],
respectively).
In addition to the isolated glaucoma samples the
genotype, allele and combined genotype data were also
obtained of 9 POAG Punjabi families consisting of 29 affected
(19 male, 10 female) and 68 non-affected (33 male, 35
female). As in the sporadic cases the combined genotype AC/
GA was found at a higher frequency in the males from the
affected families (26%) as compared to the random control
population (14%) but this difference was statistically not
Figure 2. Sequence chromatograms of
the region of XRCC1 and XPD
containing the respective SNP’s. A-C:
XRCC1 c.1316G>A (p.Arg399Gln)
variants, homozygous GG (A),
heterozygous GA (B), and homozygous
AA (C). D-F: XPD c.2298A>C
(p.Lys751Gln) variants, homozygous
AA (D), heterozygous AC (E), and
homozygous CC (F).
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significant (z=1.3 [p>0.05]; data not shown). As opposed to
this the combined genotype AA/GG was not found in any of
the affected male in the families, which when compared with
the healthy control males 35% distribution was statistically
significant (z=3.11 [p=0.001]). The AA/GA genotype was
also present at a higher frequency in the female control
population (21%) as compared to the female patients in the
families (10%), though this was not statistically significant
(z=0.8 [p>0.05]), this genotype was present at a particularly
higher frequency in the non-affected females of one family
(Figure 3).
Of the 15 XRCC1 and 15 XPD samples that were
sequenced all of the sequence data matched with the RFLP
results thus validating the latter data (Figure 2).
DISCUSSION
The integrity of the genome is continuously challenged
exogenously and endogenously by DNA damaging agents,
which induce a wide variety of lesions in the DNA including
single and double strand breaks, oxidative lesions and
pyrimidine dimer formation [4]. These lesions are efficiently
repaired by several pathways that include BER and NER
mechanisms, which are regulated by DNA repair genes
[17-19]. Of these, BER is believed to be the major pathway
for repairing deaminated bases and bases with oxidative
damage caused by reactive oxygen species, BER can also be
involved in repairing alkylated bases [20]. As opposed to this
the NER pathway is involved in removing short segments of
nucleotides containing damaged bases [21].
XRCC1, a component of the BER cascade acts as a
scaffold for other enzymes e.g., DNA ligase, DNA
polymerase, and poly ADP-ribose polymerase (a zinc finger
containing enzyme that detects DNA strand breaks) [22]. Due
to its central role in the BER pathway, amino acid changes in
XRCC1 can have detrimental effects on its activity and
subsequently on the BER mechanism. Similarly XPD has also
been shown to play a vital role in the NER pathway and thus
any non-synonymous amino acid changes in XPD can
potentially result in a defective NER mechanism [10].
Figure 3. Pedigree of the congenital
primary open angle glaucoma (POAG)
family. Normal females are represented
by circles and males by squares. Filled
squares represent affected males.
Deceased individuals are designated
with a slanting line across the symbol.
XPD and XRCC1 genotypes are shown
for each genotyped individual and the
protective genotype (AA/GA) in the
females is indicated with green letters.
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Unal et al. [23] reported XRCC1 and XPD
polymorphisms to be associated with cataract. In diseases
such as glaucoma, oxidative stress (which could be caused by
raised IOP in the eye) has been shown to increase damage to
the DNA and other macromolecules [23]. Elevated IOP is the
prime characteristic of PCAG [24] whereas degenerative
changes in the trabecular meshwork due to oxidative DNA
damage is a major contributing factor in the progression of
POAG [2]. If the oxidative stress induced DNA damage in
PCAG and POAG remains unchecked, due to failure of the
repair mechanism, it would result in enhanced DNA damage
which might lead to neurodegeneration of the optic nerve [3,
25,26].
Au et al. [27] have previously reported that due to DNA
repair defects there was an increase in the risk of chromosomal
aberrations in individuals who were heterozygous or
homozygous for the derived alleles of p.Arg399Gln and
p.Lys751Gln, this phenomenon was also observed when the
combined genotypes of these individuals were studied. To
date there is no documented evidence that shows an
association of the XRCC1 polymorphism rs25487 with
glaucoma [14]. In the current study the association of the
XRCC1 polymorphism with only the male POAG patients can
probably be attributed to the significantly higher proportion
of the GA genotype in patients as compared to controls. We
therefore postulate that in our study population XRCC1 
rs25487 has a gender specific association only with male
POAG patients. We propose that although the XRCC1
polymorphisms might not directly participate in causing
glaucoma but it can act as a hypomorph and thus could be
involved in accelerating the progression of the DNA damage
in the latter stages of the disease by hindering the DNA repair
mechanism in male patients. This is in agreement with the
observation that oxidative stress affects the optic nerve [25,
26], which could possibly be via a stress induced DNA
damage mechanism where the damage is not corrected timely
due to a defective BER pathway.
Guven et al. [14] did not observe an association of
XRCC1 or XPD polymorphisms with glaucoma in the Turkish
population, which was attributed to small sample size and lack
of ethnic homogeneity by the authors. In addition till date all
the association studies of XRCC1 or XPD polymorphisms
with glaucoma have not analyzed the data along the lines of
gender or ethnic background. We have not only studied an
ethnically pure Punjabi population, which comprises roughly
60% of the total Pakistani population but have also analyzed
the data along the lines of gender and found an association of
XRCC1 rs25487 and XPD rs13181 with male POAG patients.
One of the possible reasons for this gender specific association
could lie in the life style of the Punjabi’s, where 80% of the
population are farmers and live in rural areas. Being an
underdeveloped country antiquated methods of farming are
still in practice in Punjab where mainly the males do most of
the labor intensive outdoor work, this results in a higher degree
of exposure of the males to ambient sunlight and temperature.
Such exposures have been shown to be one of the etiological
factors causing age related ocular diseases like cataract,
pterygium and macular degeneration [27]. We thus believe
that the higher susceptibility of the Punjabi males toward the
development of the disease, as compared to the females who
mostly remain indoors, is because of the higher exposure of
the males to UV induced damage from the sunlight.
Functional analysis conducted by Lunn et al. [28]
provides an insight into the potential association of these SNPs
with disease and hence supports our results, the authors
demonstrated that sequence alterations, particularly at codon
751 of the XPD, may alter the protein product resulting in
suboptimal repair of X-ray induced DNA damage. Moreover
it has also been reported by Lehmann et al. [10] that mutations
in XPD disrupt its enzymatic functions and cause defects in
NER. We therefore hypothesize that the association of the
XPD polymorphism with POAG could be due to a defective
NER pathway that failed to repair the DNA damage caused
by oxidative stress.
The combined genotype data revealed a significant
association of the different combinations with POAG as well
as PCAG but in a gender specific manner. The association of
the AC/GA combined heterozygotes with male POAG
patients is probably because of the presence of a higher
number of XRCC1 heterozygotes (i.e., G/A) in POAG and not
because of the AC heterozygotes of XPD. This combined
genotype is also found to be present at a higher frequency in
the affected males from the families, though the difference is
statistically non-significant but that is probably due to the
smaller sample size of the affected males in the families.
Au et al. [9],  in their functional characterization of
XRCC1 and XPD SNP’s showed that the variant genotype of
the XRCC1 might only interact with variant alleles of the other
factors of BER pathways, but not with the variant genotype
of XPD that belongs to the NER pathway.
They also showed that the ancestral XRCC1 (A) and
XPD (G) as well as the ancestral combined genotypes (AA/
GG) were protective in nature. In our study this association
seems to be a male specific phenomenon as the ancestral
combined genotype (AA/GG) is present at a much lower
frequency in the female controls as compared to the male
controls. In the latter group this combined genotype seems to
have a protective role against the development of glaucoma
as it is present at a higher frequency in the controls as
compared to the patients. This combined genotype also seems
to play a role in providing protection to the males in the
families as none of the patients had this combined genotype.
Whereas in the case of sporadic female patients the combined
genotype AA/GA seems to play a protective role, which is
also the case in females from the families, particularly in one
family in which this genotype was exclusively present in the
non-affected females (Figure 3).
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To validate these results in other populations, it must be
kept in mind that any disease susceptibility or protective role
these combined genotypes play could only be cross
comparable in different populations if similarly elevated
genotype frequencies are seen in the glaucoma patients in
those populations as compared to normal control individuals.
In summary, our study is the first report that shows an
association between the XRCC1 rs25487 and XPD rs13181
polymorphisms in Pakistani male primary glaucoma patients
belonging to the dominant ethnic Punjabi group. We propose
that defects in the BER and NER pathway are probably
associated with POAG in a gender and ethnic group specific
manner. In addition we find that the AC/GA combined
genotypes might be associated with increased risk for
chromosomal damage that could be due to the reduced DNA
repair functions or selective population association of these
polymorphisms with the disease in the Pakistani Punjabi male
patients and the AA/GG genotype seems to have a protective
role against POAG in Punjabi male patients, while the AA/
GA genotype is protective in Punjabi female POAG and
PCAG patients.
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